540 related articles for article (PubMed ID: 24317439)
21. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
[TBL] [Abstract][Full Text] [Related]
22. Effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on Akt protein expression is more effective in head and neck cancer cell lineages that retain PTEN protein expression.
Pontes FSC; Pontes HAR; de Souza LL; de Jesus AS; Joaquim AMC; Miyahara LAN; Fonseca FP; Pinto Junior DS
J Oral Pathol Med; 2018 Mar; 47(3):253-259. PubMed ID: 29297949
[TBL] [Abstract][Full Text] [Related]
23. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
[TBL] [Abstract][Full Text] [Related]
24. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
[TBL] [Abstract][Full Text] [Related]
25. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
26. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
[TBL] [Abstract][Full Text] [Related]
27. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.
Saturno G; Valenti M; De Haven Brandon A; Thomas GV; Eccles S; Clarke PA; Workman P
Oncotarget; 2013 Aug; 4(8):1185-98. PubMed ID: 23852390
[TBL] [Abstract][Full Text] [Related]
28. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
[TBL] [Abstract][Full Text] [Related]
29. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
30. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
31. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
32. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
33. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells.
Wang J; Li Y; Sun W; Liu J; Chen W
Hematology; 2018 Oct; 23(9):620-625. PubMed ID: 29566599
[TBL] [Abstract][Full Text] [Related]
35. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
36. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
[TBL] [Abstract][Full Text] [Related]
38. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
[TBL] [Abstract][Full Text] [Related]
39. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
Li DJ; Shi M; Wang Z
Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
[TBL] [Abstract][Full Text] [Related]
40. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells.
To KK; Yu L; Liu S; Fu J; Cho CH
Mol Carcinog; 2012 Jun; 51(6):449-64. PubMed ID: 21678497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
